Department of Imaging and Interventional Radiology; Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China.
Quant Imaging Med Surg. 2011 Dec;1(1):35-40. doi: 10.3978/j.issn.2223-4292.2011.08.03.
Superparamagnetic iron oxide (SPIO) MR contrast agents are composed of nano-sized iron oxide crystals coated with dextran or carboxydextran. Two SPIO agents are clinically approved, namely: ferumoxides (Feridex in the USA, Endorem in Europe) with a particle size of 120 to 180 nm, and ferucarbotran (Resovist) with a particle size of about 60 nm. The principal effect of the SPIO particles is on T2* relaxation and thus MR imaging is usually performed using T2/T2*-weighted sequences in which the tissue signal loss is due to the susceptibility effects of the iron oxide core. Enhancement on T1-weighted images can also be seen with the smaller Resovist. Both Feridex and Resovist are approved specifically for MRI of the liver. The difference being that Resovist can be administered as a rapid bolus (and thus can be used with both dynamic and delayed imaging), whereas Feridex needs to be administered as a slow infusion and is used solely in delayed phase imaging. In the liver, these particles are sequestered by phagocytic Kupffer cells in normal reticuloendothelial system (RES), but are not retained in lesions lacking Kupffer cells. Consequently, there are significant differences in T2/T2* relaxation between normal tissue and lesions, resulting in increased lesion conspicuity and detectability. SPIO substantially increase the detectability of hepatic metastases. For focal hepatocellular lesions, SPIO-enhanced MR imaging exhibits slightly better diagnostic performance than dynamic CT. A combination of dynamic and static MR imaging technique using T1- and T2 imaging criteria appears to provide clinically more useful patterns of enhancement. Feridex and Resovist are also used for evaluating macrophage activities in some inflammatory lesions, but their clinical values remain to be further confirmed. The clinical development of Ferumoxtran (Combidex in the USA, Sinerem in Europe), designed for lymph node metastasis evaluation, is currently stopped.
超顺磁性氧化铁(SPIO)磁共振对比剂由纳米级氧化铁晶体与葡聚糖或羧基葡聚糖组成。有两种 SPIO 制剂已在临床上获得批准,即:粒径为 120-180nm 的 Ferumoxides(美国的 Feridex,欧洲的 Endorem)和粒径约为 60nm 的 Ferucarbotran(Resovist)。SPIO 颗粒的主要作用是影响 T2弛豫,因此磁共振成像通常使用 T2/T2-加权序列进行,其中组织信号丢失是由于氧化铁核心的磁化率效应所致。较小的 Resovist 也可以在 T1 加权图像上看到增强。Feridex 和 Resovist 均专门用于肝脏 MRI。两者的区别在于,Resovist 可以快速推注给药(因此可用于动态和延迟成像),而 Feridex 需要缓慢输注给药,仅用于延迟相成像。在肝脏中,这些颗粒被正常网状内皮系统(RES)中的吞噬性库普弗细胞隔离,但不会在缺乏库普弗细胞的病变中保留。因此,正常组织和病变之间的 T2/T2*弛豫存在显著差异,导致病变的显著性和可检测性增加。SPIO 极大地提高了肝转移瘤的检测能力。对于局灶性肝细胞病变,SPIO 增强磁共振成像显示出略优于动态 CT 的诊断性能。使用 T1 和 T2 成像标准的动态和静态磁共振成像技术的组合似乎提供了更具临床实用价值的增强模式。Feridex 和 Resovist 也用于评估某些炎症病变中的巨噬细胞活性,但它们的临床价值仍有待进一步确认。用于评估淋巴结转移的 Ferumoxtran(美国的 Combidex,欧洲的 Sinerem)的临床开发目前已停止。